{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:58:32Z","timestamp":1791687512758,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ygyno.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T20:28:01Z","timestamp":1517776081000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities"],"prefix":"10.1016","volume":"149","author":[{"given":"Kathleen N.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.01.011_bb0005","series-title":"Cancer Facts & Figures 2017","volume":"2017","author":"American Cancer Society","year":"2017"},{"issue":"5","key":"10.1016\/j.ygyno.2018.01.011_bb0010","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2018.01.011_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.tjog.2016.01.003","article-title":"Robot-assisted versus conventional laparoscopic surgery for endometrial cancer staging: a meta-analysis","volume":"55","author":"Chen","year":"2016","journal-title":"Taiwan. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.011_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.011_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.011_bb0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2016.10.006","article-title":"Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients","volume":"69","author":"Vergote","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.ygyno.2018.01.011_bb0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2018.01.011_bb0040","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2018.01.011_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2018.01.011_bb0050","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10023","key":"10.1016\/j.ygyno.2018.01.011_bb0055","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ygyno.2018.01.011_bb0060","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.01.011_bb0065","series-title":"LYNPARZA\u2122 (olaparib) capsules, for oral use. prescribing information","year":"2014"},{"issue":"9","key":"10.1016\/j.ygyno.2018.01.011_bb0070","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2018.01.011_bb0075","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.011_bb0080","author":"FDA"},{"key":"10.1016\/j.ygyno.2018.01.011_bb0085","author":"FDA"},{"key":"10.1016\/j.ygyno.2018.01.011_bb0090","series-title":"Lynparza\u2122 (olaparib) capsules, for oral use. Summary of Product Characteristics","author":"EMA","year":"2014"},{"issue":"15","key":"10.1016\/j.ygyno.2018.01.011_bb0095","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.011_bb0100","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2018.01.011_bb0105","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ygyno.2018.01.011_bb0110","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.011_bb0115","author":"FDA"},{"issue":"9","key":"10.1016\/j.ygyno.2018.01.011_bb0120","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.011_bb0125","author":"Whelton","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.011_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mcna.2016.08.016","article-title":"Guidelines for the Management of Hypertension","volume":"101","author":"Chobanian","year":"2017","journal-title":"Med. Clin. North Am."},{"issue":"5","key":"10.1016\/j.ygyno.2018.01.011_bb0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.011_bb0140","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-related fatigue, version 2.2015","volume":"13","author":"Berger","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2018.01.011_bb0145","author":"NCI"},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.011_bb0150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/PHM.0000000000000083","article-title":"Effect of exercise on cancer-related fatigue: a meta-analysis","volume":"93","author":"Tomlinson","year":"2014","journal-title":"Am. J. Phys. Med. Rehabil."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581830043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581830043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T11:50:41Z","timestamp":1575633041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581830043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S009082581830043X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}